Caitlin Costello, MD / Paul G. Richardson, MD - ‘Four’ Every Patient: Maximizing Outcomes in Newly Diagnosed Multiple Myeloma Care With Anti-CD38 Monoclonal Antibody–Based Quadruplet Therapies

Marina Chiara Garassino, MD / Edgardo S. Santos, MD, FACP, FASCO - Personalizing Care in Squamous NSCLC: From Test Results to Tailored Immunotherapy

Prof. Solange Peters, MD, PhD / David Harpole, MD - Perioperative Immunotherapy: A Multidisciplinary Blueprint for Optimizing Outcomes in Resectable NSCLC

Charu Aggarwal, MD, MPH / Benjamin Levy, MD, FASCO - Rapid Roundup in NSCLC: Keeping Up with ADC Therapies Driving Precision Lung Cancer Care

Michael Postow, MD - Enhancing First-Line Treatment Selection in Advanced Melanoma: A Patient-Centered Approach

Mark Awad, MD, PhD / Carl M. Gay, MD, PhD - Breaking News in Small-Cell Lung Cancer: Expert Insights on B7-H3–Directed Antibody–Drug Conjugates From Recent Congresses

Wells A. Messersmith, MD - Illustrating the Journey to Improved Outcomes for MSI-H/dMMR Metastatic CRC: Bringing Immunotherapy-Based Regimens to the Forefront

Caron Jacobson, MD - Where Do Antibody–Drug Conjugates Fit in Relapsed/Refractory Diffuse Large B-Cell Lymphoma? Addressing Community Questions and Real-World Approaches to Selecting and Sequencing Novel Therapies

Luis Paz-Ares, MD, PhD / Lauren Averett Byers, MD - Shaping the Future of SCLC Treatment: Advancing Care Through Innovative Approaches

Christine Brezden-Masley, MD, PhD, FRCPC - Reducing Risk of Recurrence in HR+, HER2-, High-Risk Early Breast Cancer: Optimizing Risk Stratification and Use of Adjuvant CDK4/6 Inhibitors

Komal Jhaveri, MD, FACP, FASCO - From Theory to Practice: Integrating TROP2 ADCs in HR+/HER2- Breast Cancer

Arielle Elkrief, MD / Normand Canty - Cases in Metastatic NSCLC: Optimizing Long-term Outcomes With Frontline Immunotherapy-Based Regimens

Arielle Elkrief, MD - Navigating Neoadjuvant, Adjuvant, and Perioperative Immunotherapy in Resectable High-Risk Melanoma: Tailoring Care for Optimal Outcomes

Alison Sehgal, MD - The Case for CAR T-Cell Therapy in Second-Line R/R LBCL: A Framework for Long-Term Success

Edward B. Garon, MD, MS - A Case of Best Practices: Optimizing First-Line Chemoimmunotherapy for Advanced Squamous NSCLC

Luis Paz-Ares, MD, PhD / Kristin Higgins, MD - Creating a Roadmap to Optimize Care for Patients With LS-SCLC: Integrating the Evidence Into Practical Care

Sonia Pernas, MD, PhD / Joyce O'Shaughnessy, MD / Hans Wildiers, MD, PhD - Case-Based Insights Into HER2-Low and -Ultralow Metastatic Breast Cancer: Elevating Patient Outcomes With ADCs

Pasi A. Jänne, MD, PhD, FASCO - Translating the Latest Evidence on First-Line Treatment for EGFR-Mutated NSCLC Into Practice: An Update for Community Clinicians

Barbara Melosky, MD, FRCPC / Hossein Borghaei, DO, MS - Towards Durable Outcomes: Personalizing Frontline Immunotherapy-Based Regimens in Advanced NSCLC

Andrew M. Brunner, MD - FLT3 Inhibitors in Action: Clinical Case Challenges in Newly Diagnosed AML